Search
Bepotastine
go.drugbank.com/drugs/DB04890ApprovedBepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the … It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.
NP-50301
go.drugbank.com/drugs/DB05662ExperimentalThe majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.
Fenoxaprop-ethyl
go.drugbank.com/drugs/DB05252ExperimentalFenoxaprop-ethyl (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance.
Categories: Compounds used in a research, industrial, or household settingDigoxin Immune Fab (Ovine)
go.drugbank.com/drugs/DB00076ApprovedIt is used as an antidote for overdose of digoxin.
Dinitrochlorobenzene
go.drugbank.com/drugs/DB11831InvestigationalDinitrochlorobenzene has been used in trials studying the treatment of HIV Infections.
Categories: Compounds used in a research, industrial, or household settingEstrone
go.drugbank.com/drugs/DB00655ApprovedIt is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. … Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol.
Nitrocefin
go.drugbank.com/drugs/DB11592ExperimentalNitrocefin is a chromogenic cephalosporin substrate used to detect the presence of beta-lactamase enzymes, an important mediator of bacterial antibiotic resistance.
Categories: Compounds used in a research, industrial, or household settingNNZ-2591
go.drugbank.com/drugs/DB15601InvestigationalIt was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalIt has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.
SPP 301
go.drugbank.com/drugs/DB05290InvestigationalSPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.